MDxHealth, the maker of prostate cancer diagnostics, just acquired Dutch liquid biopsy company NovioGendix for $8.8 million. With the new urine-based test, slated for release next year under the name SelectMDx, it aims to reduce unnecessary biopsies for prostate cancer.
Molecular diagnostics company MDxHealth and partner NovioGendix have been awarded a $1.1 million grant that will be applied toward research and development of a new bladder cancer diagnostic. Belgium-based MDxHealth (BRU:MDXH), which has its U.S. headquarters in Durham, North Carolina, develops companion diagnostics for cancer treatments. The grant to MDxHealth and Dutch molecular diagnostics firm […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.